RODERICK WONG

CIK 1493280 · Chief Executive Officer · last filed 2026-07-23

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$378.67M

Companies

16

Total Filings

56

Lifetime Open-Market Net

$70.38M

Filer Profile

Reported Address
C/O RTW INVESTMENTS, LP
40 10TH AVENUE, 7TH FLOOR
NEW YORK, NY 10014
Related Filers
RTW INVESTMENTS, LP — 87 joint filings, latest 2026-07-23
RTW MASTER FUND, LTD. — 11 joint filings, latest 2025-11-13
Naveen Yalamanchi — 10 joint filings, latest 2021-08-31
RTW Innovation Master Fund Ltd. — 4 joint filings, latest 2025-11-13
RTW Fund Group GP, LLC — 2 joint filings, latest 2026-07-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALLURION TECHNOLOGIES, INC. (ALUR) Delisted 10%+ Owner 0 $8.70 $0 $0 1 2026-07-23
RCKT Director 18,263,956 $3.35 $61.18M -$32.05M 11 2026-07-06
OBIO 10%+ Owner 9,556,063 $6.12 $58.48M -$264 4 2026-04-29
KLRA 10%+ Owner 10,776,820 $13.94 $150.23M $16.00M 1 2026-04-22
RCKTW Director 18,218,457 $0.00 $36.4K $0 5 2025-07-18
CARGO Therapeutics, Inc. (CRGX) Delisted 10%+ Owner 5,175,832 $4.47 $23.14M $0 1 2024-01-16
Orchestra BioMed Holdings, Inc. (HSAQ) Delisted Chief Executive Officer 2,808,512 $13.31 $37.38M $28.10M 2 2023-01-26
MIST 10%+ Owner 4,315,102 $0.98 $4.23M $374.6K 6 2022-09-09
Renovacor, Inc. (RCOR.WS) Delisted 10%+ Owner 3,000,803 $0.07 $213.1K $18.41M 4 2022-01-20
RNA Director $10.36 $0 1 2021-06-17
Landos Biopharma, Inc. (LABP) Delisted Director 62,500 $22.93 $1.43M $20.00M 1 2021-02-08
DermTech, Inc. (DMTK) Delisted 10%+ Owner 2,887,216 $0.09 $271.4K $3.59M 3 2020-08-19
TELA 10%+ Owner 1,175,358 $0.97 $1.14M $554.2K 1 2019-12-17
Immunovant, Inc. (HSACW) Delisted Chief Executive Officer 902,498 $9.27M 12 2019-12-13
STOK 10%+ Owner 3,560,682 $29.03 $103.37M $6.13M 1 2019-11-06
PENWEST PHARMACEUTICALS CO (PPCO) Delisted Director 0 $0 2 2010-09-22

Recent Filings · Page 3 of 6

56 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-01-03 Renovacor, Inc. (RCOR.WS) Delisted Buy (P) +13,989 $111.8K EDGAR
2021-12-28 Renovacor, Inc. (RCOR.WS) Delisted Buy (P) +199,467 $1.59M EDGAR
2021-09-07 Renovacor, Inc. (RCOR.WS) Delisted Buy (P) +1,600,000 $16.00M EDGAR
2021-06-17 RNA Grant (A) $0 EDGAR
2021-06-16 RCKT Grant (A) $0 EDGAR
2021-05-24 MIST Buy (P) $0 EDGAR
2021-05-13 RCKT Mixed −2,175,000 -$87.07M EDGAR
2021-02-08 Landos Biopharma, Inc. (LABP) Delisted Mixed +8,551,444 $20.00M EDGAR
2020-10-29 MIST Buy (P) $0 EDGAR
2020-08-19 DermTech, Inc. (DMTK) Delisted Exer (X) +62,900 $600.1K EDGAR
Showing 2130 of 56
Page 3 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.